We provide you with 20 years of free, institutional-grade data for APLS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of APLS. Explore the full financial landscape of APLS stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-07-31 | 1492422 | APLS | 10-Q | Url |
| 2025-05-07 | 1492422 | APLS | 10-Q | Url |
| 2025-02-28 | 1492422 | APLS | 10-K | Url |
| 2024-11-05 | 1492422 | APLS | 10-Q | Url |
| 2024-08-01 | 1492422 | APLS | 10-Q | Url |
| 2024-05-07 | 1492422 | APLS | 10-Q | Url |
| 2024-02-27 | 1492422 | APLS | 10-K | Url |
| 2023-11-01 | 1492422 | APLS | 10-Q | Url |
| 2023-07-31 | 1492422 | APLS | 10-Q | Url |
| 2023-05-04 | 1492422 | APLS | 10-Q | Url |
| 2023-02-21 | 1492422 | APLS | 10-K | Url |
| 2022-11-07 | 1492422 | APLS | 10-Q | Url |
| 2022-08-08 | 1492422 | APLS | 10-Q | Url |
| 2022-05-04 | 1492422 | APLS | 10-Q | Url |
| 2022-02-28 | 1492422 | APLS | 10-K | Url |
| 2021-11-08 | 1492422 | APLS | 10-Q | Url |
| 2021-08-09 | 1492422 | APLS | 10-Q | Url |
| 2021-04-28 | 1492422 | APLS | 10-Q | Url |
| 2021-02-25 | 1492422 | APLS | 10-K | Url |
| 2020-11-02 | 1492422 | APLS | 10-Q | Url |
| 2020-07-30 | 1492422 | APLS | 10-Q | Url |
| 2020-04-29 | 1492422 | APLS | 10-Q | Url |
| 2020-02-27 | 1492422 | APLS | 10-K | Url |
| 2019-11-05 | 1492422 | APLS | 10-Q | Url |
| 2019-07-31 | 1492422 | APLS | 10-Q | Url |
| 2019-05-07 | 1492422 | APLS | 10-Q | Url |
| 2019-02-26 | 1492422 | APLS | 10-K | Url |
| 2018-11-13 | 1492422 | APLS | 10-Q | Url |
| 2018-07-31 | 1492422 | APLS | 10-Q | Url |
| 2018-04-30 | 1492422 | APLS | 10-Q | Url |
| 2018-04-16 | 1492422 | APLS | S-1 | Url |
| 2018-03-19 | 1492422 | APLS | 10-K | Url |
| 2017-12-20 | 1492422 | APLS | 10-Q | Url |
| 2017-10-13 | 1492422 | APLS | S-1 | Url |
| 2015-10-13 | 1492422 | APLS | S-1 | Url |
Apellis Pharmaceuticals, Inc(NASDAQ:APLS) 
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials fo...
Website: http://www.apellis.com
Founded: 2009
Full Time Employees: 350
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about APLS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.